Dendrite Acquires Assets of OPUS Health, a Leading Supplier of Patient Persistence Technology

Dendrite International, Inc. (NASDAQ:DRTE) a leadingprovider of sales and marketing solutions to the pharmaceuticalindustry, today announced the acquisition of substantially all theassets of OPUS Health LLC, a leading provider of direct-to-patientpersistence technologies. The acquisition cements an existingagreement between the two companies that enables Dendrite to providethe industry's most complete end-to-end, multi-channel persistencesolution, which links pharmaceutical companies, prescribers,pharmacies and patients. OPUS Health will operate as a division ofDendrite within the Marketing Solutions business.

Patient persistence is a far-reaching problem for all keyhealthcare constituents: patient, provider, payor,pharmaceutical/biotech manufacturer, pharmacy and government. Simplyput, when patients don't take their medications properly, it lessensthe health benefit for the patient and thereby increases costs for theentire system. Dendrite believes patient persistence programs will bea large market and ultimately evolve into an even larger diseasemanagement market.

OPUS Health is an early-stage company and pioneer indirect-to-patient technologies. Dendrite adds its breadth of marketingservices around OPUS Health technology to deliver complete patientpersistence programs and analysis. As partners, Dendrite and OPUSHealth have already provided such programs for more than 40pharmaceutical brands. This strategic acquisition allows Dendrite toreinforce its early lead in the first generation of electronicdirect-to-patient programs and position it for leadership in futuregenerations of these technologies.

"The acquisition of OPUS Health is consistent with our strategy tobe a leader in direct-to-patient persistence solutions," said CarlCohen, president of Dendrite Marketing Solutions. "Patients respond tothe solution because of its ease of use, instant point-of-sale nature,and availability at their local pharmacies. Our customers and otherhealthcare constituents value the end-to-end nature of our programs,which improve patient health and help lower overall costs."

"Dendrite has always been an industry visionary and we are glad tobe joining the Dendrite family," said Harvey Brofman, vice presidentand general manager of the OPUS Health group at Dendrite. "With theacquisition of OPUS Health into its Marketing Solutions group,Dendrite has a more powerful, streamlined solution in the area ofpatient persistence. We also believe that being part of Dendrite canenhance our product offering to partners and strengthen ourrelationships with them."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enablessales, marketing, clinical and compliance solutions for the globalpharmaceutical industry. The Company's clients are located in morethan 50 countries and include the world's top 20 pharmaceuticalcompanies. For more information, please visit www.dendrite.com. Formore information on OPUS Health, please visit www.opushealth.com.

About OPUS Health

OPUS Health assets were sold to Dendrite by OCI Ventures, LLC aprivately held company whose other Division, OPUS-ISM, LLC is aleading provider of pharmacy management systems and pharmacy workflowtechnology to retail pharmacies, HMOs and PBMs.

Note: Dendrite is a registered trademark of DendriteInternational, Inc.

This document may contain forward-looking statements that may beidentified by such forward-looking terminology as "expect," "believe,""anticipate," "will," "intend," "plan," "target," "outlook,""guidance," and similar statements or variations. Such forward-lookingstatements are based on our current expectations, estimates,assumptions and projections and involve significant risks anduncertainties, including risks which may result from our dependence onthe pharmaceutical industry; our fixed expenses in relation tofluctuating revenues and variations in customers' budget cycles;dependence on certain major customers, including the risk associatedwith one substantial customer currently assessing its U.S. sales forceeffectiveness services needs; our ability to successfully implementour Operational Effectiveness program and to achieve the cost savingsin the amounts and time periods expected or budgeted; changes indemand for our products and services attributable to any weaknessexperienced in the economy or mergers, acquisitions and consolidationsin the pharmaceutical industry; risks associated with foreign currencyfluctuations and our ability to adapt and respond successfully toother unique risks involved in our non-U.S. operations; integratingthe entities we acquire; and our ability to effectively manage ourgrowth. Other important factors that should be reviewed and carefullyconsidered are included in the company's 10-K, 10-Qs, and otherreports filed with the SEC. Actual results may differ materially. Thecompany assumes no obligation for updating any such forward-lookingstatements to reflect actual results, changes in assumptions or otherchanges affecting such forward-looking statements and the informationprovided in this press release should not be construed as updating,modifying or confirming the company's most recent financial outlook orguidance.